Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the effect of Tranexamic Acid Oral Solution 5% in patients treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple tooth extraction.


Clinical Trial Description

The purpose of this study is to compare the efficacy, acceptability, and safety of Tranexamic Acid Oral Solution 5% with placebo in the prevention of clinically relevant bleeding events in subjects treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple tooth extraction. A total of approximately 280 subjects will be randomized in two equal treatment groups (approximately 140 subjects per group) to receive Tranexamic Acid Oral Solution 5% or placebo solution for 7 days. Following screening, eligible subjects can be randomized within 14 days when all eligibility criteria are confirmed. Randomized subjects will undergo tooth extraction(s) and treatment period. The treatment period ends at Visit 5 followed by the follow-up period. The maximal study duration is about 4 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06143787
Study type Interventional
Source Hyloris Developments
Contact Christophe Lyssens
Phone +3243460207
Email clinical@hyloris.com
Status Recruiting
Phase Phase 3
Start date November 7, 2023
Completion date June 27, 2024